Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted Oncology
J B AuliacR Gervais

Abstract

Retrospective studies suggested a benefit of first-line tyrosine kinase inhibitor (TKI) treatment continuation after response evaluation in solid tumors (RECIST) progression in epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. The aim of this multicenter observational retrospective study was to assess the frequency of this practice and its impact on overall survival (OS). The analysis included advanced EGFR-mutated NSCLC patients treated with first-line TKI who experienced RECIST progression between June 2010 and July 2012. Among the 123 patients included (67 ± 12.7 years, women: 69 %, non smokers: 68 %, PS 0-1: 87 %), 40.6 % continued TKI therapy after RECIST progression. There was no difference between the patients who did and did not continue TKI therapy with respect to progression-free survival (PFS1: 10.5 versus 9.5 months, p = 0.4). Overall survival (OS) showed a non-significant trend in favor of continuing TKI therapy (33.0 vs. 21.2 months, p = 0.054). Progressions were significantly less symptomatic in the TKI continuation group than in the discontinuation group (18 % vs. 37 %, p < 0.01). Univariate analysis showed a higher risk of death among patients with PS >1 (HR 4.33, 95 %...Continue Reading

References

May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert S BenjaminChuslip Charnsangavej
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyMark Kozloff
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David JackmanVincent A Miller
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L BlackwellJoyce O'Shaughnessy
Nov 26, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ho Yun LeeMyung Jin Chung
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Oct 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kenichi NishieMinoru Takada
Oct 20, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jin-Ji YangYi-Long Wu
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Andrew J WeickhardtD Ross Camidge
Dec 21, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Mizuki NishinoBruce E Johnson
Jul 3, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fabio ConfortiTommaso Martino De Pas
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Sep 11, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·K NishinoA Kumanogoh
Dec 7, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hye-Ryoun KimKye Young Lee
Sep 2, 2014·European Respiratory Review : an Official Journal of the European Respiratory Society·Alexis B Cortot, Pasi A Jänne
Sep 13, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Christos ChouaidAlain Vergnenegre

❮ Previous
Next ❯

Citations

Oct 28, 2018·Cellular Oncology (Dordrecht)·Heidi FettkeArun A Azad
Mar 14, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J GaoJ-Y Ding
Oct 11, 2019·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Camille MehlmanEtienne Giroux Leprieur
Sep 16, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Mayo-de-Las-CasasM A Molina-Vila

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.